Continuous Manufacturing has attracted significant interest for small molecules formulated as drug products in the last decade. CM now also becomes increasingly relevant for large molecules, for both quality and business reasons. As biologics are complex to produce there are numerous challenges.

In this lead article in ‘Pharmaceutical Engineering’ (ISPE), the authors discuss design and operation considerations, drivers for moving to a CBM platform, implementation of new technologies and regulatory requirements.

Continuous manufacturing is gaining momentum, offering significant advantages over traditional Very Large-Scale (VLS) approaches.

Just – Evotec Biologics was thrilled to host a visit from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to its Seattle and J.POD^® Redmond, WA (US) facilities.

This visit was part of the Manufacturing Optimization Program effort to enhance the U.S. Government’s rapid response capabilities for biologics medical counter measures in response to emergency situations.

Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DODs Manufacturing Optimization Program.

Our new J.POD^® Toulouse, France (EU) biomanufacturing facility provides high productivity, low cost and easily scalable production of drug substance from early clinical supply through to commercial manufacturing.